

**Chronic kidney disease: Early identification and management of chronic
disease in adults in primary and secondary care (partial update)**

National Clinical Guideline Centre

4th Guideline Development Group Meeting

Date and Time: 1st February 2013 10:00 – 16:00

Place: NCGC, 180 Great Portland Street, London

Invited:

Paul Stevens, Chair (PS)

Technical team

Caroline Blaine, Research Fellow
Lisbeth Hoeg-Jensen, Project Manager
Lilian Li, Health Economist (LL)
Jill Parnham, Guideline Lead (JP)
Sharon Swain, Senior research fellow

GDG members

Paula D'Souza, Renal Nurse
Hugh Gallagher, Nephrologist
Kathryn Griffith, GP
Karen Jenkins, Renal Nurse
Paul Kendrew, Renal Pharmacist
Ed Lamb, Clinical Biochemist
Robert Lewis, Nephrologist
Fiona Loud, Lay member
Shelagh O'Riordan, Geriatrician
Nicholas Palmer, Lay member (until 1 pm)

NICE

Ben Doak, NICE Guideline Commissioning Manager (until 1 pm)

Apologies

Paul Roderick, Professor of Public health
Richard Whittome, Information Scientist

Minutes

- 1. Introductions and apologies.** PS welcomed everyone to the meeting.
- 2. Declarations of Interest.** All GDG members were asked to verbally declare any new declarations of interests since GDG 3. New declarations of interests were declared by Fiona Loud and Robert Lewis:

Fiona Loud declared that she had just received (31-01-2013) an unexpected personal fee from Shire for an interview in March 2012. This was declared at the time as 'non personal pecuniary'. It was agreed that this would be further explored outside of the GDG meeting but that for the

questions under debate today, no conflict of interest was apparent.

Kathryn Griffiths had an earlier DOI regarding AF (Pfizer) (expires 11th July 2013) that meant she had to leave the meeting during the discussions in the afternoon of the evidence review for anti-platelet and anti-thrombotic therapy question. Chairs action: declare and withdraw for Q11 at this GDG meeting.

The GDG queried whether members' participation in the development of the KDIGO guideline and authorship of related articles should also be declared. This was confirmed as the KDIGO guideline e.g. describes measurement of GFR which is also part of the GDG's review areas.

- 3. Draft working notes and NICE minutes from GDG3.** The draft working notes and NICE minutes from GDG3 were agreed with the correction of the name of a GDG member and the name of a mentioned journal.
- 4. Clinical pathway for health economic analysis.** LL presented the draft clinical pathway for one of the prioritised economic review areas. The GDG discussed the presentation and content of the draft clinical pathway.
- 5. Evidence review: Self-management systems, including information and support for use of self-management support systems.** The evidence reports were presented by SC and the GDG discussed draft recommendations.
- 6. Evidence review: Anti-platelet and anti-thrombotic therapy.** The evidence report was presented by SC and the GDG discussed draft recommendations.
- 7. Any other business.** The review protocol regarding AKI and risk of CKD was agreed and signed off by the GDG. The evidence reports for hyperuricemia and low protein diet were signed off. Fiona Loud reminded the GDG about the World Kidney Day on 14 March 2013 and asked for any input to the website www.worldkidneyday.co.uk.

Date, time and venue of the next meeting:

8th March 2013, 10:00 – 16:00, Boardroom, NCGC offices, 180 Great Portland Street